Randomized Controlled Trial

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3,...

Lancet Respir Med. 2020 May 1; 8 (5): 461-474.
Randomized Controlled Trial

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.

Ann. Allergy Asthma Immunol. 2021 Feb 1; 126 (2): 187-193.
Article

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.

Resp Res. 2020 Oct 13; 21 (1): 265.